z-logo
open-access-imgOpen Access
Expression of Adhesion Molecules on Myeloma Cells
Author(s) -
Tatsumi Tetsuya,
Shimazaki Chihiro,
Goto Hideo,
Araki Shinichi,
Sudo Yoshikazu,
Yamagata Noboru,
Ashihara Eishi,
Inaba Tohru,
Fujita Naohisa,
Nakagawa Masao
Publication year - 1996
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.1996.tb02108.x
Subject(s) - multiple myeloma , cd38 , cell adhesion molecule , cd44 , flow cytometry , cancer research , microbiology and biotechnology , cd11a , biology , integrin alpha m , immunology , cell , cd18 , cd34 , stem cell , biochemistry
We investigated the expression of adhesion molecules including LFA‐1α (CD11a), Mac‐1 (CD11b), LFA‐1β (CD18), VLA‐β 1 , (CD29), H‐CAM (CD44), VLA‐4 (CD49d), VLA‐5 (CD49e), ICAM‐1 (CD54), N‐CAM (CD56), LFA‐3 (CD58), VNR‐β (CD61), and LECAM‐1 (CD62L) on fresh myeloma cells and human myeloma cell lines. By two‐color flow cytometric analysis with anti‐CD38 antibody, we demonstrated that myeloma cells were located in the strongly CD38‐positive (CD38 ++ ) fractions. Fresh myeloma cells were obtained from 28 patients with multiple myeloma (MM) and 3 patients with plasma cell leukemia (PCL). All myeloma cells expressed VLA‐4 on their surface. Most of the myeloma cells also expressed VLA‐5, ICAM‐1, and LFA‐3. H‐CAM was strongly expressed in 3 cases of PCL and 2 cases of aggressive myeloma, and moderately expressed in other MMs. N‐CAM was expressed in 68% of MMs, but none of the 3 PCLs. LFA‐1 was expressed in two cases of aggressive myeloma, but not expressed in other non‐aggressive myelomas. Most of the myeloma cells did not express Mac‐1, VNR‐β, or LECAM‐1. These results suggest that VLA‐4, VLA‐5, ICAM‐1, LFA‐3, and H‐CAM are involved in cellular interaction and migration in MM, and that the expression of N‐CAM and LFA‐1 varies with disease activity in MM.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here